- Home
- PLX vs PGZ Comparison
PLX vs PGZ Comparison
Compare PLX & PGZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLX
- PGZ
- Stock Information
- Founded
- PLX 1993
- PGZ 2012
- Country
- PLX Israel
- PGZ United States
- Employees
- PLX N/A
- PGZ N/A
- Industry
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- PGZ Investment Managers
- Sector
- PLX Health Care
- PGZ Finance
- Exchange
- PLX Nasdaq
- PGZ Nasdaq
- Market Cap
- PLX 79.4M
- PGZ 71.0M
- IPO Year
- PLX 1998
- PGZ N/A
- Fundamental
- Price
- PLX $1.69
- PGZ $10.59
- Analyst Decision
- PLX
- PGZ
- Analyst Count
- PLX 0
- PGZ 0
- Target Price
- PLX N/A
- PGZ N/A
- AVG Volume (30 Days)
- PLX 484.0K
- PGZ 23.0K
- Earning Date
- PLX 11-14-2024
- PGZ 01-01-0001
- Dividend Yield
- PLX N/A
- PGZ 12.26%
- EPS Growth
- PLX N/A
- PGZ N/A
- EPS
- PLX N/A
- PGZ N/A
- Revenue
- PLX $45,667,000.00
- PGZ N/A
- Revenue This Year
- PLX N/A
- PGZ N/A
- Revenue Next Year
- PLX $88.94
- PGZ N/A
- P/E Ratio
- PLX N/A
- PGZ N/A
- Revenue Growth
- PLX N/A
- PGZ N/A
- 52 Week Low
- PLX $0.82
- PGZ $8.46
- 52 Week High
- PLX $1.90
- PGZ $10.59
- Technical
- Relative Strength Index (RSI)
- PLX 74.21
- PGZ 45.87
- Support Level
- PLX $1.60
- PGZ $10.36
- Resistance Level
- PLX $1.75
- PGZ $10.60
- Average True Range (ATR)
- PLX 0.12
- PGZ 0.14
- MACD
- PLX 0.04
- PGZ 0.01
- Stochastic Oscillator
- PLX 85.48
- PGZ 39.32
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
About PGZ Principal Real Estate Income Fund of Beneficial Interest
Principal Real Estate Income Fund is a non-diversified, closed-end management investment company. Its investment objective is to provide high current income with capital appreciation by investing in commercial real estate-related securities.